Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | STAT6 | P42226 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3503521 | 0.91 | HSD17B10 (0.64) | HSD17B10KDM4ESLC6A9S1PR1ALOX15 | |
| Tetraxetan SCHEMBL2017956 | 0.91 | HSD17B10 (0.64) | HSD17B10KDM4ESLC6A9S1PR1ALOX15 | |
| Tetraxetan SCHEMBL18018 | 0.91 | HSD17B10 (0.64) | HSD17B10KDM4ESLC6A9S1PR1ALOX15 | |
| SCHEMBL6744121 | 0.91 | HSD17B10 (0.64) | HSD17B10KDM4ESLC6A9S1PR1ALOX15 | |
| SCHEMBL321989 | 0.91 | HSD17B10 (0.64) | HSD17B10KDM4ESLC6A9S1PR1ALOX15 | |
| Tetraxetan SCHEMBL2635294 | 0.91 | HSD17B10 (0.64) | HSD17B10KDM4ESLC6A9S1PR1ALOX15 | |
| SCHEMBL6848102 | 0.91 | HSD17B10 (0.64) | HSD17B10KDM4ESLC6A9S1PR1ALOX15 | |
| SCHEMBL173508 | 0.91 | HSD17B10 (0.64) | HSD17B10KDM4ESLC6A9S1PR1ALOX15 | |
| SCHEMBL3660521 | 0.91 | — | — | |
| SCHEMBL15043622 | 0.90 | KDM4E (0.58) | HSD17B10KDM4ESLC6A9ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813340-B2 | PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-11-14 | — | — | US | disclosed |
| US-20210220493-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| EP-3749653-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | The Johns Hopkins University (US) | 2020-12-16 | — | — | EP | disclosed |
| CN-112020497-A | PSMA-targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy | 约翰霍普金斯大学 | 2020-12-01 | — | — | CN | disclosed |
| WO-2019157037-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220493-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | PSMA1, PSMA3, PSMA2 | HSD17B10 3973/4885KDM4E 824/4885SLC6A9 1624/4885 |
| US-11813340-B2 | PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy | PSMA1, PSMA3, PSMA2 | HSD17B10 3973/4885KDM4E 824/4885SLC6A9 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.